6533b7d3fe1ef96bd12615e5

RESEARCH PRODUCT

Whole‐body magnetic resonance imaging (WB‐MRI) in lymphoma: State of the art

Domenico AlbanoMassimo GaliaAlberto BrunoMassimo MidiriCorrado TarellaCorrado TarellaGiuseppe MicciCaterina Patti

subject

Cancer Researchmedicine.medical_specialtyLymphomaWhole body imagingFollicular lymphoma03 medical and health sciences0302 clinical medicineimmune system diseaseshemic and lymphatic diseasesmedicineAnimalsHumansT-cell lymphomaWhole Body ImagingB-cell lymphomaAnaplastic large-cell lymphomaNeoplasm Stagingbusiness.industryHematologyGeneral Medicinemedicine.diseaseMagnetic Resonance ImagingPeripheral T-cell lymphomaOncology030220 oncology & carcinogenesisMantle cell lymphomaRadiologybusinessDiffuse large B-cell lymphoma030215 immunology

description

The improvements in magnetic resonance imaging (MRI) technology and the concern related to the increased cancer risk in patients with lymphoma, also due to radiation exposure associated with imaging examinations, have led to the introduction of whole-body MRI (WB-MRI) as a radiation-free alternative to standard imaging procedures. WB-MRI seems a less histology-dependent functional imaging test than 18 F-fluorodeoxyglucose-positron emission tomography/CT (18 F-FDG-PET/CT). In patients with FDG-avid lymphomas, such as diffuse large B-cell lymphoma (DLBCL) and Hodgkin lymphoma (HL), 18 F-FDG-PET/CT remains the imaging reference standard for staging, with WB-MRI potentially being a complementary modality that could replace CT, especially in young patients. On the other hand, WB-MRI is a valuable imaging procedure for lymphoma surveillance and in lymphomas with variable/low FDG avidity and nonfollicular indolent lymphomas. The aim of this paper is to discuss the current state of the art of WB-MRI in lymphoma by evaluating its diagnostic performance in different lymphoma subtypes: Hodgkin, aggressive, and indolent lymphomas.

yearjournalcountryeditionlanguage
2019-07-28Hematological Oncology
https://doi.org/10.1002/hon.2676